AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
MIAMI BEACH -- Gestational exposure to azithromycin was not associated with an increased risk above baseline for major fetal anomalies in a prospective, controlled trial of 369 pregnant women.
The antibiotic had a safety profile comparable to the profiles of other nonteratogenic agents.
The results suggest that the drug may be a good first-line choice for some infections in pregnancy, particularly among traditionally noncompliant populations, because of its demonstrated efficacy and simple one-dose regimen, Moumita Sarkar reported in a poster presentation at the annual meeting of the American Society for Clinical Pharmacology and Therapeutics.
To date, available human studies ad dressing gestational use of azithromycin have focused primarily on efficacy, not fetal safety. "It's clear the drug is effective, but is it safe to use during pregnancy? These findings give professionals caring for pregnant women an evidence-based option for treating infections," said Ms. Sarkar of the Hospital for Sick Children in Toronto.
She and her associates at the hospital evaluated the pregnancy outcomes of 123 women who were treated with azithromycm for a range of indications including skin, upper and lower respiratory tract, and genitourinary infections. Of the 123 women, 88 were treated during the first trimester.
The outcomes were compared with those of 123 women receiving nonteratogenic antibiotics for similar indications and 123 women receiving other nonteratogenic agents.
The three groups were matched for gestational age at the time the drug was prescribed, maternal age, and smoking and alcohol status.